Evolving Management of Low‐Density Lipoprotein Cholesterol: A Personalized Approach to Preventing Atherosclerotic Cardiovascular Disease Across the Risk Continuum

Author:

Wilkinson Michael J.1ORCID,Lepor Norman E.23ORCID,Michos Erin D.4ORCID

Affiliation:

1. Division of Cardiovascular Medicine, Department of Medicine University of California San Diego San Diego CA

2. David Geffen School of Medicine at University of California, Los Angeles CA Los Angeles

3. Cedars‐Sinai Medical Center Los Angeles CA

4. Division of Cardiology Johns Hopkins University School of Medicine Baltimore MD

Abstract

Management of elevated low‐density lipoprotein cholesterol (LDL‐C) is central to preventing atherosclerotic cardiovascular disease (ASCVD) and key to reducing the risk of ASCVD events. Current guidelines on the management of blood cholesterol recommend statins as first‐line therapy for LDL‐C reduction according to an individual's ASCVD risk and baseline LDL‐C levels. The addition of nonstatin lipid‐lowering therapy to statins to achieve intensive LDL‐C lowering is recommended for patients at very high risk of ASCVD events, including patients with familial hypercholesterolemia who have not achieved adequate LDL‐C lowering with statins alone. Despite guideline recommendations and clinical trial evidence to support the use of lipid‐lowering therapies for ASCVD risk reduction, most patients at high or very high risk do not meet LDL‐C thresholds. This review explores the challenges associated with LDL‐C lowering in contemporary clinical practice and proposes a framework for rethinking the binary definition of ASCVD, shifting from “primary” versus “secondary” prevention to a “continuum of risk.” The approach considers the role of plaque burden and progression in subclinical disease and emphasizes the importance of early risk assessment and treatment for preventing first cardiovascular events. Patients at high risk of ASCVD events who require significant LDL‐C lowering should be considered for combination therapies comprising statin and nonstatin agents. Practical guidance for the pharmacological management of elevated LDL‐C, both now and in the future, is provided.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cardiology and Cardiovascular Medicine

Cited by 3 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3